## 3 Experimental Results

Table 6: List of molecules detected (S/N \(\geq\) 3) in the breath of the twenty healthy subjects and four CKD-affected patients prior to undergoing a kidney transplant. \begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline _Peak n\({}^{\circ}\)_ & _RT a (min)_ & \begin{tabular}{c} _Common Compound_ \\ _Name_ \\ \end{tabular} & \begin{tabular}{c} _Match_ \\ **(\%)** \\ \end{tabular} & \begin{tabular}{c} _Probability_ \\ **(\%)** \\ \end{tabular} & \begin{tabular}{c} _Standard identity_ \\ **Confirmation b** \\ \end{tabular} & \
\begin{tabular}{c} _Healthy_ \\ _Subjects_ \\ \end{tabular} &
\begin{tabular}{c} _CKD_ \\ _Patients_ \\ \end{tabular} \\ \hline
36 & 13.8 & **2-Butanone_** & 948 & 96 & yes & yes & yes \\ \hline
37 & 14.1 & Heptene & 899 & 88 & yes & yes & yes \\ \hline
38 & 14.3 & 3-Hexanol & 866 & 77 & & yes & yes \\ \hline
39 & 14.9 & Acetic acid & 915 & 67 & & yes & yes \\ \hline
40 & 15.9 & 2-Propanol-1-methoxy & 838 & 52 & & yes & yes \\ \hline
41 & 16.4 & 1,4-Dioxane & 828 & 51 & & yes & yes \\ \hline
42 & 16.6 & 2-Pentanone & 903 & 89 & & yes & yes \\ \hline
43 & 16.7 & **Butanoic acid** & 933 & 97 & yes & yes & yes \\ \hline
44 & 17.4 &
\begin{tabular}{c} Cyclotrisiloxane \\ hexamethyl \\ \end{tabular} & 807 & 58 & & yes & yes \\ \hline
45 & 17.5 & **Toluene** & 938 & 97 & yes & yes & yes \\ \hline
46 & 18.2 & Unidentified & 907 & 70 & & & yes \\ \hline
47 & 18.4 & 2-Hexanone & 881 & 68 & & yes & yes \\ \hline
48 & 19.6 & **Hexanal** & & & yes & yes \\ \hline
49 & 19.8 & Methyl isobutyl ketone & 902 & 76 & & yes & yes \\ \hline
50 & 20.00 &
\begin{tabular}{c} Hexanoic acid, methyl \\ ester \\ \end{tabular} & 874 & 83 & & & yes & yes \\ \hline
51 & 20.1 & Nonane & 934 & 54 & yes & yes & yes \\ \hline
52 & 20.3 &
\begin{tabular}{c} Pentanoic acid, methyl \\ ester \\ \end{tabular} & 879 & 79 & & & yes & yes \\ \hline
53 & 20.5 & Pentanoic acid & 809 & 54 & yes & yes & yes \\ \hline
54 & 22.2 & Di(isobutyl)acetone & 815 & 58 & & yes & yes \\ \hline
55 & 22.4 & **Hexanoic acid** & 879 & 79 & yes & yes & yes \\ \hline
56 & 23.0 & **3-Heptanone** & 918 & 82 & yes & yes & yes \\ \hline
57 & 23.2 &
\begin{tabular}{c} Heptanoic acid, methyl \\ ester \\ \end{tabular} & 988 & 83 & & yes & yes \\ \hline
58 & 23.5 &
\begin{tabular}{c} Eptane, \\ 2,2,4,6,6-pentamethyl \\ \end{tabular} & 888 & 55 & & yes & yes \\ \hline
59 & 23.9 &
\begin{tabular}{c} Tetrasiloxane, \\ decamethyl \\ \end{tabular} & 848 & 51 & & yes & yes \\ \hline
60 & 24.8 & Limonene & 915 & 92 & & yes & yes \\ \hline
61 & 25.1 &
\begin{tabular}{c} Butanoic acid, dimethyl \\ ester \\ \end{tabular} & 855 & 74 & & yes & yes \\ \hline
62 & 25.7 & **Benzaldehyde** & 933 & 95 & yes & yes & yes \\ \hline
63 & 25.9 &
\begin{tabular}{c} Octanoic acid, methyl \\ ester \\ \end{tabular} & 832 & 68 & & yes & yes \\ \hline
64 & 26.2 & Decane & 932 & 55 & yes & yes \\ \hline
65 & 26.8 &
\begin{tabular}{c} Benzoic acid, methyl \\ ester \\ \end{tabular} & 815 & 54 & & yes & yes \\ \hline
66 & 27.5 & 1-Decanol-2-esil & 877 & 53 & & yes & yes \\ \hline
67 & 27.8 & lbruprofen & 984 & 83 & & & yes \\ \hline
68 & 28.3 & **Dodecane** & 928 & 54 & yes & yes & yes \\ \hline
69 & 29.0 & Unidentified & & & yes & yes \\ \hline \hline \end{tabular}
\end{table} 
Table 6: _Cont._Finally, the concentration range of the thirteen selected target compounds was estimated for both the healthy subjects and/or the CKD-affected patient populations. The experimental results are presented in Table 7.